Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

palvella therapeutics - PVLA

PVLA

Close Chg Chg %
76.69 3.21 4.19%

Closed Market

79.90

+3.21 (4.19%)

Volume: 471.28K

Last Updated:

Feb 2, 2026, 4:00 PM EDT

Trade Now

Company Overview: palvella therapeutics - PVLA

PVLA Key Data

Open

$78.94

 Day Range

78.94 - 82.46

52 Week Range

12.60 - 114.69

 Market Cap

$907.74M

Shares Outstanding

11.84M

 Public Float

8.08M

Beta

-0.16

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$4.81

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

235.72K

  

PVLA Performance

1 Week
 
 4.19%
 
1 Month
 
 -20.32%
 
3 Months
 
 0.08%
 
1 Year
 
 514.62%
 
5 Years
 
 -65.08%
 

PVLA Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 16
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Palvella Therapeutics - PVLA

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
- 31.42M 25.90M 42.81M
Sales Growth
+7.14% -17.56% +65.28% -100.00%
Cost of Goods Sold (COGS) incl D&A
- 2.37M 2.78M 1.78M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
- 2.37M 2.78M 1.78M
Depreciation
- 2.37M 2.78M 1.78M
Amortization of Intangibles
- - - -
-
COGS Growth
- +17.40% -35.94% -100.00%
Gross Income
- 29.05M 23.12M 41.03M
Gross Income Growth
- -20.41% +77.45% -100.00%
Gross Profit Margin
- +92.46% +89.27% +95.84%
2021 2022 2023 2024 5-year trend
SG&A Expense
80.88M 66.60M 56.87M 14.10M
Research & Development
64.20M 50.21M 40.02M 8.15M
Other SG&A
16.68M 16.38M 16.85M 5.94M
SGA Growth
+32.34% -17.66% -14.60% -75.22%
Other Operating Expense
- - - -
-
Unusual Expense
- - 13.91M 1.51M
-
EBIT after Unusual Expense
(51.83M) (43.47M) (29.76M) (15.61M)
Non Operating Income/Expense
6.09M 10.20M 5.21M 2.49M
Non-Operating Interest Income
- 4.00K 721.00K 1.85M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- - - 4.32M
-
Interest Expense Growth
- - - -
-
Gross Interest Expense
- - - 4.32M
-
Interest Capitalized
- - - -
-
Pretax Income
(45.74M) (33.28M) (24.54M) (17.43M)
Pretax Income Growth
-23.40% +27.24% +26.25% +28.97%
Pretax Margin
- -145.58% -128.47% -57.33%
Income Tax
- - - -
-
Income Tax - Current - Domestic
- - - -
-
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(45.74M) (33.28M) (24.54M) (17.43M)
Minority Interest Expense
- - - -
-
Net Income
(45.74M) (33.28M) (24.54M) (17.43M)
Net Income Growth
-22.85% +27.24% +26.25% +28.97%
Net Margin Growth
- -145.58% -128.47% -57.33%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(45.74M) (33.28M) (24.54M) (17.43M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(45.74M) (33.28M) (24.54M) (17.43M)
EPS (Basic)
-56.688 -35.892 -21.8008 -7.8322
EPS (Basic) Growth
-3.69% +36.69% +39.26% +64.07%
Basic Shares Outstanding
806.84K 927.15K 1.13M 2.23M
EPS (Diluted)
-56.688 -35.892 -21.8008 -7.8322
EPS (Diluted) Growth
-3.69% +36.69% +39.26% +64.07%
Diluted Shares Outstanding
806.84K 927.15K 1.13M 2.23M
EBITDA
(49.46M) (40.69M) (14.06M) (14.10M)
EBITDA Growth
-55.57% +17.73% +65.44% -0.23%
EBITDA Margin
- -157.44% -157.11% -32.85%

Snapshot

Average Recommendation BUY Average Target Price 185.063
Number of Ratings 16 Current Quarters Estimate -0.907
FY Report Date 03 / 2026 Current Year's Estimate -3.961
Last Quarter’s Earnings -0.96 Median PE on CY Estimate N/A
Year Ago Earnings -3.518 Next Fiscal Year Estimate -5.587
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 10 10 16 13
Mean Estimate -0.91 -0.92 -3.96 -5.59
High Estimates -0.81 -0.77 -2.94 -2.81
Low Estimate -1.03 -1.11 -5.05 -10.06
Coefficient of Variance -7.93 -12.14 -17.60 -45.40

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 16 16 12
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Palvella Therapeutics in the News